Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain

Neuropharmacology

Volumn 57, Issue 2, 2009, Pages 121-126

  Chen, Shao Rui ^a   Samoriski, Gary ^b   Pan, Hui Lin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Glutamate; Glutamatergic input; NMDA receptors; Pain; Spinal cord; Synaptic transmission

Indexed keywords

GABAPENTIN; MEMANTINE; NERAMEXANE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; HYPERALGESIA; LOW DRUG DOSE; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT;

AMINES; ANALGESICS; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOPENTANES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; MALE; MEMANTINE; PAIN; PAIN MEASUREMENT; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STREPTOZOCIN; TIME FACTORS;

EID: 67650167699     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.04.010     Document Type: Article

References (47)

1. Amin P., and Sturrock N.D. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet. Med. 20 (2003) 114-118
2. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., LaMoreaux L., and Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
3. Begon S., Pickering G., Eschalier A., and Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res. 887 (2000) 436-439
4. Brown M.J., and Asbury A.K. Diabetic neuropathy. Ann. Neurol. 15 (1984) 2-12
5. Bruins Slot L.A., Tarayre J.P., Koek W., Ribet J.P., and Colpaert F.C. Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats. Pharmacol. Biochem. Behav. 72 (2002) 943-951
6. Calcutt N.A., and Chaplan S.R. Spinal pharmacology of tactile allodynia in diabetic rats. Br. J. Pharmacol. 122 (1997) 1478-1482
7. Carlsson K.C., Hoem N.O., Moberg E.R., and Mathisen L.C. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol. Scand. 48 (2004) 328-336
8. Carlton S.M., Rees H., Tsuruoka M., and Willis W.D. Memantine attenuates responses of spinothalamic tract cells to cutaneous stimulation in neuropathic monkeys. Eur. J. Pain 2 (1998) 229-238
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
10. Chaplan S.R., Malmberg A.B., and Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J. Pharmacol. Exp. Ther. 280 (1997) 829-838
11. Chen S.R., Eisenach J.C., McCaslin P.P., and Pan H.L. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology 92 (2000) 500-506
12. Chen S.R., Khan G.M., and Pan H.L. Antiallodynic effect of intrathecal neostigmine is mediated by spinal nitric oxide in a rat model of diabetic neuropathic pain. Anesthesiology 95 (2001) 1007-1012
13. Chen S.R., and Pan H.L. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats. J. Neurophysiol. 87 (2002) 2726-2733
14. Chen S.R., and Pan H.L. Up-regulation of spinal muscarinic receptors and increased antinociceptive effect of intrathecal muscarine in diabetic rats. J. Pharmacol. Exp. Ther. 307 (2003) 676-681
15. Clark Jr. C.M., and Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N. Engl. J. Med. 332 (1995) 1210-1217
16. Correll G.E., Maleki J., Gracely E.J., Muir J.J., and Harbut R.E. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 5 (2004) 263-275
17. Courteix C., Eschalier A., and Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 (1993) 81-88
18. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 9 (2008) 253-257
19. Danysz W., Gossel M., Zajaczkowski W., Dill D., and Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?-case of amantadine and memantine. J. Neural. Transm. Parkinson's Dis. Dement. Sect. 7 (1994) 155-166
20. Danysz W., Parsons C.G., Jirgensons A., Kauss V., and Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr. Pharm. Des. 8 (2002) 835-843
21. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A.M., Eschalier A., and Fialip J. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-d-aspartate-dependent mechanisms. Mol. Pharmacol. 70 (2006) 1246-1254
22. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41 (1991) 773-780
23. Eide K., Stubhaug A., Oye I., and Breivik H. Continuous subcutaneous administration of the N-methyl-d-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 61 (1995) 221-228
24. Fisher K., Coderre T.J., and Hagen N.A. Targeting the N-methyl-d-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J. Pain Symptom Manage. 20 (2000) 358-373
25. Foster A.C., and Wong E.H. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-d-aspartate receptor in rat brain. Br. J. Pharmacol. 91 (1987) 403-409
26. Gortelmeyer R., and Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung 42 (1992) 904-913
27. Hesselink M.B., Parsons C.G., Wollenburg C., and Danysz W. Brain distribution of an uncompetitive NMDA receptor antagonist; comparison to its in vitro potency in electrophysiological studies. Naunyn Schmiedebergs Arch. Pharmacol. 360 (1999) 144-150
28. Hesselink M.B., Smolders H., De Boer A.G., Breimer D.D., and Danysz W. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration. Behav. Pharmacol. 10 (1999) 85-98
29. Huettner J.E., and Bean B.P. Block of N-methyl-d-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1307-1311
30. Johnson J.W., and Kotermanski S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 6 (2006) 61-67
31. Khan G.M., Chen S.R., and Pan H.L. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 114 (2002) 291-299
32. Klein T., Magerl W., Hanschmann A., Althaus M., and Treede R.D. Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur. J. Pain 12 (2008) 17-29
33. Kornhuber J., Weller M., Schoppmeyer K., and Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural. Transm. Suppl. 43 (1994) 91-104
34. Malcangio M., and Tomlinson D.R. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76 (1998) 151-157
35. Max M.B., Byas-Smith M.G., Gracely R.H., and Bennett G.J. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin. Neuropharmacol. 18 (1995) 360-368
36. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., and Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38 (1999) 85-108
37. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
38. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., and Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34 (1995) 1239-1258
39. Periclou A., Ventura D., Rao N., and Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin. Pharmacol. Ther. 79 (2006) 134-143
40. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9 (2003) 275-308
41. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
42. Sang C.N., Booher S., Gilron I., Parada S., and Max M.B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 96 (2002) 1053-1061
43. Suzuki R., Matthews E.A., and Dickenson A.H. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain 91 (2001) 101-109
44. Tomiyama M., Furusawa K., Kamijo M., Kimura T., Matsunaga M., and Baba M. Upregulation of mRNAs coding for AMPA and NMDA receptor subunits and metabotropic glutamate receptors in the dorsal horn of the spinal cord in a rat model of diabetes mellitus. Brain Res. Mol. Brain Res. 136 (2005) 275-281
45. Wang X.L., Zhang H.M., Chen S.R., and Pan H.L. Altered synaptic input and GABAB receptor function in spinal superficial dorsal horn neurons in rats with diabetic neuropathy. J. Physiol. 579 (2007) 849-861
46. Zoladz P.R., Campbell A.M., Park C.R., Schaefer D., Danysz W., and Diamond D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol. Biochem. Behav. 85 (2006) 298-306
47. Zurek J.R., Nadeson R., and Goodchild C.S. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain 90 (2001) 57-63